Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR2 | P34972 | 4/20 | 0.52 |
| ▸ | CNR1 | P21554 | 8/20 | 0.47 |
| ▸ | TDO2 | P48775 | 1/20 | 0.45 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.44 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.44 |
| ▸ | CHRM1 | P11229 | 2/20 | 0.43 |
| ▸ | TACR2 | P21452 | 1/20 | 0.42 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.40 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.40 |
| ▸ | ANO1 | Q5XXA6 | 2/20 | 0.39 |
| ▸ | TAS1R3 | Q7RTX0 | 1/20 | 0.39 |
| ▸ | TAS1R1 | Q7RTX1 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18725365 | 0.81 | CHRM1 (0.55) | CNR2PDCD1CD274CHRM1 | |
| SCHEMBL18756556 | 0.81 | CHRM1 (0.55) | CNR2PDCD1CD274CHRM1 | |
| SCHEMBL18725439 | 0.77 | CNR1 (0.49) | CNR2CNR1TDO2CHRM1 | |
| SCHEMBL18756367 | 0.76 | CHRM1 (0.58) | CNR2PDCD1CD274CHRM1 | |
| SCHEMBL18725391 | 0.76 | CHRM1 (0.58) | CNR2PDCD1CD274CHRM1 | |
| SCHEMBL18725385 | 0.76 | CHRM1 (0.58) | CNR2PDCD1CD274CHRM1 | |
| SCHEMBL29934007 | 0.74 | CNR1 (0.49) | CNR2CNR1TDO2TACR2TAS1R3 | |
| SCHEMBL18725446 | 0.74 | CNR1 (0.52) | CNR2CNR1CHRM1TACR2ANO1 | |
| SCHEMBL18725447 | 0.74 | CNR1 (0.52) | CNR2CNR1CHRM1TACR2ANO1 | |
| SCHEMBL18725444 | 0.74 | CNR1 (0.52) | CNR2CNR1CHRM1TACR2ANO1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3156397-B1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICALS CO (JP) | 2019-08-07 | — | — | EP | disclosed |
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2017-05-04 | — | — | US | disclosed |
| EP-3156397-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | Takeda Pharmaceutical Company Limited (JP) | 2017-04-19 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170121308-A1 | NITROGEN-CONTAINING HETEROCYCLIC COMPOUND | CHRM1, CHRM5, CHRM2 | CNR2 55/4885CNR1 27/4885TDO2 3420/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.